SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The community is rallying behind the multichain meme project crow with knife, highlighting its deflationary burn mechanism and organic growth as primary drivers of their bullish sentiment. Discussions are dominated by high-energy engagement and a strong conviction that the token serves as a unique asset within the current meme coin landscape.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in popularity as the community rallies around its status as a long-standing parody of Bitcoin, with users debating whether its satirical roots give it staying power as a legitimate asset. Supporters are actively pointing to its unique lore, growing holder count, and high-profile endorsements as catalysts, while others remain skeptical, fueling a polarized discussion about its long-term potential in the meme coin space.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as institutional investors debate whether the sector's aggressive AI-driven rally is facing a distribution phase or a continuation setup. The community is heavily focused on the disconnect between soaring AI infrastructure capex and mounting concerns over data center cancellations, power grid constraints, and valuation premiums.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently facing intense selling pressure and negative sentiment as investors express frustration over prolonged stagnant price action and its consistent underperformance compared to other assets. The community is actively debating the project's long-term utility versus its speculative nature, while many are focused on the impact of upcoming legislative developments and potential accumulation opportunities during this period of high volatility.

DaVita, Inc. engages in the provision of medical care services. It operates through the US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offer kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consists primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

DaVita Inc

DaVita is currently trending as investors weigh the potential long-term impact of GLP-1 weight-loss drugs on the demand for dialysis services, leading to significant market volatility. While some community members view the sharp price drop as a major overreaction based on distant speculation, others are actively debating the sustainability of the company's business model and debt load in light of emerging medical treatments.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is seeing intense market activity fueled by speculation over potential high-profile partnerships and its integration into the decentralized live music and event ecosystem. Community sentiment remains polarized, with many investors highlighting strong momentum and real-world utility while others caution against potential volatility and speculative 'pump and dump' patterns.

Maulcoin

Maulcoin is trending as its community aggressively rallies behind the project's organic growth and 'join the dark side' branding, with members actively pushing for social engagement and new listings to drive the next wave of price appreciation. Investors are heavily focused on holding through dips and hitting specific market cap milestones that trigger community-wide airdrops, highlighting a strong collective sentiment centered on long-term accumulation rather than short-term gains.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently trending as a leading proxy for SpaceX, driven by investor optimism surrounding a potential high-valuation IPO and the company's significant equity stake acquired through recent spectrum deals. Market participants are actively debating the company's valuation metrics and the potential for a short squeeze, positioning the stock as a high-beta setup tied to the upcoming space sector catalysts.

IDEX

IDEX is trending as investors speculate on potential price breakouts, with the community actively debating whether the asset is primed for a rally driven by technical chart patterns and new protocol liquidity initiatives. Market participants are split between bullish sentiment regarding recent consolidation and skepticism fueled by the stock's history of volatility and rapid price swings.

TON (The Open Network) is a general-purpose&nbsp;blockchain that allows developers to build decentralized apps and tokens.

Toncoin

Toncoin is capturing market attention as its integration with Telegram reaches a massive user base, with traders highlighting recent sub-second network upgrades and high APY staking opportunities. Community discussion is currently centered on increased institutional adoption, including new ETP listings and strategic whale accumulation despite recent price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SG Americas Securities LLC Cuts Stock Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

SG Americas Securities LLC lowered its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 74.4% during the 4th quarter, according to the company in its most recent...

Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Aberdeen Group plc cut its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 54.9% during the fourth quarter, according to its most recent Form 13F filing with the...

How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval

LLY wins FDA nod for oral obesity pill Foundayo, boosting shares as it eyes billions in sales and a fast catch-up to rivals in the booming GLP-1 market.

Capricorn Fund Managers Ltd Invests $17.57 Million in Structure Therapeutics Inc. Sponsored ADR $GPCR

Capricorn Fund Managers Ltd bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most...

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eighteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with...

Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8% - What's Next?

Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 10.8% - Still a Buy...

LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?

Eli Lilly stock gains on FDA nod for oral obesity drug Foundayo, expanding its portfolio and patient access, setting up a fresh showdown with Novo Nordisk in the GLP-1 market.

Exchange Traded Concepts LLC Sells 32,241 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Exchange Traded Concepts LLC lowered its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 55.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,981 shares of the company's stock after...

What's Going On With Structure Therapeutics Stock On Wednesday?

Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment, boosting sentiment.read more...

<ul class="summary-bullets"><li>Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss.</li><li>Structure Therapeutics expects to initiate late-stage clinical development of its experimental drug Aleniglipron in the second half of 2026.</li><li>According to data from Koyfin, GPCR stock carries a 12-month average target of $109, while VKTX stock carries a 12-month average target of $92.72.</li></ul>Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are capturing intense investor attention as obesity treatments are increasingly deemed the largest growth engine in the U.S. pharmaceutical industry.Eli Lilly (LLY) and Novo Nordisk (NVO) currently dominate the current obesity drug market. Smaller firms Viking and Structure are both developing drugs for obesity even as bigger names like Pfizer (PFE) and AstraZeneca (AZN) also seek to enter the competition ring.<h2 class="st-heading-2">Viking, Structure’s Obesity Pipelines</h2>Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. The trial enrolled about 1,000 patients with type 2 diabetes and who have obesity or who are overweight, the company said.The primary endpoint of the study is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The dual agonist VK2735 is being developed in both oral and subcutaneous formulations. Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.Meanwhile, Structure said earlier this month that its experimental drug Aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16.0% at the 240 mg dose at 44 weeks in a mid-stage trial. The company now expects to initiate late-stage clinical development of the drug in the second half of 2026.The company also has other investigational obesity drugs called ACCG-2671 and ANPA-0073 currently in early stage studies. &nbsp;<h2 class="st-heading-2">Who Offers Better Upside?</h2>According to data from Koyfin, GPCR carries a 12-month average target of $109, implying a 147.95% upside potential from its last close. The stock holds a consensus analyst rating of 'Strong Buy', with 15 analysts rating the stock ‘Buy’ or higher while one rates it a ‘Hold’.Meanwhile, VKTX carries a 12-month average target of $92.72, representing a 209.80% upside from current levels. The stock also holds a consensus 'Strong Buy' rating, with 17 analysts rating it ‘Buy’ or higher while two hate it ‘Hold’.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment toward VKTX stock stayed within the ‘neutral’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Meanwhile, sentiment toward GPCR stock stayed within the ‘bearish’ territory, while message volume fell from ‘normal’ to ‘low’ levels. &nbsp;<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has climbed 24% this year, while <a href="https://stocktwits.com/symbol/GPCR">GPCR</a> surged 154%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gm-doubles-down-on-heavy-duty-gas-trucks-amid-massive-ev-writedowns-report/cZERzvHRINm">GM Doubles Down On Heavy-Duty Gas Trucks Amid Massive EV Writedowns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Injections for weight loss with Semaglutide. An obese woman gives a hormone glucagon-like peptide-1 (GLP-1) injection into the abdomen with a pen syringe.

VKTX Vs. GPCR: Which Obesity Drug Developer Does Wall Street See With The Bigger Upside?

According to analyst valuations, Structure Therapeutics may offer 148% potential upside, compared to an upside of 210% on Viking Therapeutics. 

Equity

According to analyst valuations, Structure Therapeutics may offer 148% potential upside, compared to an upside of 210% on Viking Therapeutics. 


Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GPCR News

GPCRStructure Therapeutics Inc - ADR